Next Article in Journal
Effect of a 6-Week Cycle of Nordic Walking Training on Vitamin 25(OH)D3, Calcium-Phosphate Metabolism and Muscle Damage in Multiple Myeloma Patients–Randomized Controlled Trial
Previous Article in Journal
High Expressed Emotion (HEE), Assessed Using the Five-Minute Speech Sample (FMSS), as a Predictor of Psychiatric Relapse in Patients with Schizophrenia and Major Depressive Disorder: A Meta-Analysis and Meta-Regression
 
 
Review
Peer-Review Record

Multicentric Reticulohistiocytosis Associated with an Early Form of Systemic Lupus Erythematosus: A Case Report of a Rare Disease, with Mini Review of the Literature

J. Clin. Med. 2022, 11(21), 6529; https://doi.org/10.3390/jcm11216529
by Elena Biancamaria Mariotti 1,*, Alberto Corrà 1, Elisa Lemmi 2, Lucrezia Laschi 2, Cristina Aimo 1, Lavinia Quintarelli 3, Walter Volpi 4, Francesca Nacci 5, Alice Verdelli 4, Valentina Ruffo di Calabria 1, Serena Guiducci 5 and Marzia Caproni 3
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2022, 11(21), 6529; https://doi.org/10.3390/jcm11216529
Submission received: 19 September 2022 / Revised: 16 October 2022 / Accepted: 1 November 2022 / Published: 3 November 2022
(This article belongs to the Section Immunology)

Round 1

Reviewer 1 Report

The case report of MRH from Mariotti et al reported a successful treatment of a 50-year-old woman with MRH. The report comes with a comprehensive discussion, which is highly appreciated. However, the manuscript contains many language and grammar issues. While the treatment of tocilizumab greatly ameliorated the skin manifestations, it would be helpful if doses and durations of all treatments (including previous non-responsive treatments) are provided. It will be more valuable if underline mechanisms of different treatment options are discussed. 

Minor points:

1. It would be helpful if giant cells are pointed in Figure 3A.

2. It's contradict to say MRH interests every internal organ (in abstract), but it's actually rarely affect internal organs (Abstract, pg 2).

3. Pg 1, introduction, "RH are a group" should be "RH is a group". Suggest to check English all through.

4. Pg 9, line 30, An interesting data from our cohort of 8 patients. This is a case report. Where is your cohort?

5. Discussion, first paragraph. "Authors should discuss the results ... may also be highlighted". Where is this coming from? manuscript requirement? or accident incorporation. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

This is an interesting case presentation, followed by brief literature review, describing autoimmune manifestations that precede multicentric reticulohistiocytosis. There is a particular attention to the pattern that articular manifestations preceded dermatological ones, which was consistent with the other cases.

 

Major

1. Could the authors elaborate better the history of treatment? Especially with regards to the RA diagnosis in ?2009 followed by unsuccessful treatment. How about the lab values, when were they captured during the clinical course?

2. Could the authors provide disease activity scoring that shows disease progression? It might be a good idea to visualize it in a simple chart/plot. With chronic joint manifestations as shown in the figures, it seems possible that disease activity has been documented in this patient's medical record.

Minor

1. Please remove the first three sentences under Discussion which were included by mistake.

2. Please make the nomenclature consistent with regards to Sjögren's syndrome.

3. Please clarify the RA history with regards to rheumatoid nodules and RA diagnosis (years as currently written: 2018 and 2009).

4. Please appropriately address patient's privacy with regards to Fig. 4 (e.g black out the area surrounding eyes).

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

Everything was clarified, thank you very much.

Back to TopTop